Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fexofenadine

A Markham1, A J Wagstaff

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 20, 1998
PubMed
Summary
This summary is machine-generated.

Fexofenadine, a non-sedating antihistamine, effectively treats allergic rhinitis and chronic idiopathic urticaria. It demonstrated a favorable safety profile, with no significant QT interval prolongation and an adverse event profile similar to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Allergology
  • Clinical Trials

Background:

  • Fexofenadine is the active metabolite of terfenadine, a nonsedating H1 receptor antagonist.
  • Previous studies indicated no QT interval prolongation in animal models or human volunteers at therapeutic dosages.

Purpose of the Study:

  • To evaluate the efficacy and safety of fexofenadine in treating allergic rhinitis and chronic idiopathic urticaria.
  • To assess the cardiovascular safety of fexofenadine, specifically its effect on the QT interval.

Main Methods:

  • Double-blind clinical trials were conducted comparing fexofenadine to placebo and cetirizine.
  • Animal models were used to assess allergic response and QT interval.
  • Human volunteers received various dosages of fexofenadine for different durations.

Related Experiment Videos

Main Results:

  • Fexofenadine effectively controlled symptoms in seasonal allergic rhinitis and chronic idiopathic urticaria.
  • No significant QT interval prolongation was observed in animal studies or human trials.
  • Adverse events were comparable to placebo, with headache and fatigue being most common.

Conclusions:

  • Fexofenadine is an effective and safe treatment option for allergic rhinitis and chronic idiopathic urticaria.
  • The drug exhibits a favorable cardiovascular safety profile.
  • Fexofenadine offers a well-tolerated alternative for allergy symptom management.